This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

TherapeuticsMD Appoints Sebastian Mirkin, M.D. As Chief Medical Officer

Stocks in this article: TXMD

TherapeuticsMD, Inc. (NYSE MKT: TXMD) announced today the appointment of Sebastian Mirkin, M.D., a prominent women’s health product development executive with extensive experience in the pharmaceutical industry and clinical research, as Chief Medical Officer, effective November 25th, 2013. Dr. Brian Bernick, TherapeuticsMD’s current Chief Medical Officer, will then serve as Chief Clinical Officer.

Dr. Mirkin joins TherapeuticsMD from Pfizer, Inc. where he served as the Global Lead of Women’s Health Clinical Research and Development. Most recently, he oversaw the development and successful marketing authorization of Duavee™ (conjugated estrogens/bazedoxifene), a menopausal combination product approved by the U.S. Food and Drug Administration (FDA) earlier this month. Dr. Mirkin supervised and directed early- and late-stage clinical programs for Pfizer’s small molecule and biologic product candidates to address menopausal symptoms, osteoporosis, contraception, uterine fibroids and endometriosis. He successfully executed large phase 3 clinical trials for numerous other development programs and oversaw the filing of New Drug Applications and regulatory submissions worldwide for products addressing vasomotor symptoms associated with menopause, vulvar and vaginal atrophy, osteoporosis, and contraception, leading to marketing authorizations in the U.S., Europe and Japan.

“We are very pleased to welcome Dr. Mirkin to TherapeuticsMD. His strong and highly relevant experience overseeing successful clinical trial programs is the precise expertise we need for advancing the development of our bio-identical hormone franchise as we seek to introduce FDA-approved products that match the molecular structure of the estradiol and/or progesterone produced in a woman’s body. More specifically, we believe his work on the first new combination hormone product to come to market in more than nine years could increase the likelihood of a positive outcome for our portfolio of products,” said Robert G. Finizio, Co-Founder and Chief Executive Officer of TherapeuticsMD.

“We view his decision to join the company at this time to be a significant validation of our scientific and clinical platform, as well as the leadership role TherapeuticsMD is playing in advancing innovative treatments in the women’s hormone and health market,” concluded Finizio.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs